STRATA Skin Sciences Dirección

Dirección controles de criterios 1/4

El CEO de STRATA Skin Sciences' es Dolev Rafaeli , nombrado en Oct 2023, tiene una permanencia de menos de un año. compensación anual total es $998.71K, compuesta por 6.7% salario y 93.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 3.54% de las acciones de la empresa, por valor de $517.44K. La antigüedad media del equipo directivo y de la junta directiva es de 1.6 años y 6 años, respectivamente.

Información clave

Dolev Rafaeli

Chief Executive Officer (CEO)

US$998.7k

Compensación total

Porcentaje del salario del CEO	6.7%
Permanencia del CEO	less than a year
Participación del CEO	3.5%
Permanencia media de la dirección	1.6yrs
Promedio de permanencia en la Junta Directiva	6yrs

Actualizaciones recientes de la dirección

Recent updates

Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt In A Risky Way?

Mar 19

STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Dec 31

Health Check: How Prudently Does STRATA Skin Sciences (NASDAQ:SSKN) Use Debt?

Nov 03

We Think STRATA Skin Sciences (NASDAQ:SSKN) Has A Fair Chunk Of Debt

Jul 04

STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Stock Rockets 26% But Many Are Still Ignoring The Company

Apr 18

Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt Sensibly?

Jan 14

STRATA Skin Sciences GAAP EPS of -$0.05 in-line, revenue of $9.1M beats by $0.96M

Aug 10

Strata Skin stock soars ~18% after hours on U.S. commercial launch of acne treatment

Jul 25

What Type Of Returns Would STRATA Skin Sciences'(NASDAQ:SSKN) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Mar 09

Reflecting on STRATA Skin Sciences' (NASDAQ:SSKN) Share Price Returns Over The Last Five Years

Nov 24

STRATA Skin Sciences EPS in-line, beats on revenue

Nov 10

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Dolev Rafaeli en comparación con los beneficios de STRATA Skin Sciences?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$999k	US$67k	-US$11m
Sep 30 2023	n/a	n/a	-US$7m
Jun 30 2023	n/a	n/a	-US$7m
Mar 31 2023	n/a	n/a	-US$6m
Dec 31 2022	n/a	n/a	-US$6m
Sep 30 2022	n/a	n/a	-US$6m
Jun 30 2022	n/a	n/a	-US$6m
Mar 31 2022	n/a	n/a	-US$3m
Dec 31 2021	US$283k	US$271k	-US$3m
Sep 30 2021	n/a	n/a	-US$2m
Jun 30 2021	n/a	n/a	-US$3m
Mar 31 2021	n/a	n/a	-US$6m
Dec 31 2020	US$593k	US$412k	-US$4m
Sep 30 2020	n/a	n/a	-US$4m
Jun 30 2020	n/a	n/a	-US$4m
Mar 31 2020	n/a	n/a	-US$3m
Dec 31 2019	US$1m	US$400k	-US$4m
Sep 30 2019	n/a	n/a	-US$3m
Jun 30 2019	n/a	n/a	-US$3m
Mar 31 2019	n/a	n/a	-US$3m
Dec 31 2018	US$3m	US$289k	-US$4m

Compensación vs. Mercado: La compensación total de Dolev($USD998.71K) está por encima de la media de empresas de tamaño similar en el mercado US ($USD663.90K).

Compensación vs. Ingresos: La compensación de Dolev ha aumentado mientras la empresa no es rentable.

CEO

Dolev Rafaeli (59 yo)

less than a year

Permanencia

US$998,708

Compensación

Dr. Dolev Rafaeli, Ph D., serves as Vice-Chairman, President and Chief Executive Officer at STRATA Skin Sciences, Inc. since October 30, 2023. He served as Chief Executive Officer, President and Director o...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Dolev Rafaeli	President	less than a year	US$998.71k	3.54% $ 472.7k
Christopher Lesovitz	Chief Financial Officer	2.6yrs	US$701.89k	0.11% $ 14.6k
Shmuel Gov	Chief Operating Officer	less than a year	US$709.97k	0.057% $ 7.6k
Jay Sturm	General Counsel & Corporate Secretary	no data	sin datos	sin datos
Michael Stewart	Independent Consultant	7.5yrs	US$732.90k	sin datos

1.6yrs

Permanencia media

63yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de SSKN no se considera experimentado ( 1.6 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Dolev Rafaeli	President	less than a year	US$998.71k	3.54% $ 472.7k
Daniel Lufkin	Director Emeritus	14.1yrs	US$28.62k	sin datos
Uri Geiger	Independent Chairman	6yrs	US$80.00k	sin datos
R. Anderson	Member of Scientific Advisory Board	7yrs	US$10.25k	sin datos
Irit Yaniv	Director	less than a year	US$13.87k	sin datos
Shmuel Rubinstein	Independent Director	6yrs	US$87.20k	0.43% $ 58.0k
Wayne Cafran	Director	less than a year	US$14.28k	sin datos

6.0yrs

Permanencia media

61yo

Promedio de edad

Junta con experiencia: La junta directiva de SSKN se considera experimentada (5.9 años de antigüedad promedio).

STRATA Skin Sciences Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Strata Skin Sciences, Inc. Promotes Shmuel Gov to the Position of Chief Operating Officer

Less than half of directors are independent

STRATA Skin Sciences, Inc. Announces Management Change

STRATA Skin Sciences, Inc., Annual General Meeting, Oct 26, 2023

STRATA Skin Sciences, Inc. Announces Board Changes

STRATA Skin Sciences, Inc., Annual General Meeting, Jun 22, 2022

Recent updates

STRATA Skin Sciences, Inc. to Report Q1, 2024 Results on May 15, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 15%

No longer forecast to breakeven

Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt In A Risky Way?

STRATA Skin Sciences, Inc. to Report Q4, 2023 Results on Mar 27, 2024

STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Strata Skin Sciences, Inc. Promotes Shmuel Gov to the Position of Chief Operating Officer

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 11% to US$3.60

STRATA Skin Sciences, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Health Check: How Prudently Does STRATA Skin Sciences (NASDAQ:SSKN) Use Debt?

Less than half of directors are independent

STRATA Skin Sciences, Inc. Announces Management Change

STRATA Skin Sciences, Inc., Annual General Meeting, Oct 26, 2023

Consensus EPS estimates fall by 32%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Profitability

Forecast breakeven date moved forward to 2024

STRATA Skin Sciences, Inc. to Report Q2, 2023 Results on Aug 09, 2023

We Think STRATA Skin Sciences (NASDAQ:SSKN) Has A Fair Chunk Of Debt

STRATA Skin Sciences, Inc. Announces Board Changes

STRATA Skin Sciences, Inc. Announces First Patients Treated in TheraClear®X Clinical Study for Acne

First quarter 2023 earnings: EPS misses analyst expectations

STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Stock Rockets 26% But Many Are Still Ignoring The Company

Forecast breakeven date pushed back to 2025

Full year 2022 earnings: EPS and revenues exceed analyst expectations

STRATA Skin Sciences Announces TheraClearX Product Demonstration at Inaugural Winter Clinical Conference

STRATA Skin Sciences, Inc. Revises Revenue Guidance for the Full Year 2022

STRATA Skin Sciences, Inc. Announces Poster Accepted at ODAC Dermatology, Aesthetic & Surgical Conference

Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt Sensibly?

Consensus estimates of losses per share improve by 12%

Forecast to breakeven in 2024

STRATA Skin Sciences, Inc. Reiterates Earnings Guidance for the Year 2022

STRATA Skin Sciences Receives Non-Compliance Letter from NASDAQ

STRATA Skin Sciences, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Consensus forecasts updated

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

STRATA Skin Sciences, Inc. Provides Revenue Guidance Full Year 2022

STRATA Skin Sciences GAAP EPS of -$0.05 in-line, revenue of $9.1M beats by $0.96M

STRATA Skin Sciences, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Strata Skin Sciences Announces U.S. Commercial Launch of Theraclear®X Acne Therapy System

Strata Skin stock soars ~18% after hours on U.S. commercial launch of acne treatment

STRATA Skin Sciences, Inc., Annual General Meeting, Jun 22, 2022

Consensus forecasts updated

STRATA Skin Sciences, Inc. Names Michael E. Goodman as Head of International Sales

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

STRATA Skin Sciences, Inc. Provides Earnings Guidance for the Year 2022

Price target decreased to US$4.30

STRATA Skin Sciences, Inc. Appoints Patricia S. Walker to Its Board of Director

STRATA Skin Sciences Announces Commercial Launch of XTRAC Momentum 1.0 and First Installation in the U.S

STRATA Skin Sciences, Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2021

Third quarter 2021 earnings released: US$0.015 loss per share (vs US$0.037 loss in 3Q 2020)

Price target increased to US$4.80

Independent Director recently bought US$104k worth of stock

Second quarter 2021 earnings released: EPS US$0.032 (vs US$0.05 loss in 2Q 2020)

STRATA Skin Sciences, Inc. (NasdaqCM:SSKN) entered into a definitive agreement to acquire U.S. Dermatology Business of Ra Medical Systems, Inc. from Ra Medical Systems, Inc. (NYSEAM:RMED) for $3.7 million.

Price target increased to US$4.20

Independent Director Samuel Navarro has left the company

Consensus EPS estimates fall to -US$0.17

First quarter 2021 earnings released: US$0.072 loss per share (vs US$0.031 loss in 1Q 2020)

Consensus forecasts updated

Full year 2020 earnings released: US$0.13 loss per share (vs US$0.11 loss in FY 2019)

Strata Skin Sciences Announces Expanded Distribution Agreement in China with Wuhan Miracle Laser Systems, Inc

What Type Of Returns Would STRATA Skin Sciences'(NASDAQ:SSKN) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

STRATA Skin Sciences, Inc. Announces Executive Changes

CEO, President & Director Dolev Rafaeli has left the company

STRATA Skin Sciences, Inc. to Report Q4, 2020 Results on Mar 24, 2021

New 90-day high: US$2.16